Aethlon Medical to Merge with North Immunology

NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech

July 17, 2026

Biotechnology

NextCure and Avere Therapeutics have entered into a definitive all-stock merger that will create a publicly traded biotechnology company focused on developing once-weekly oral therapies for inflammatory diseases driven by interleukin-23. The transaction is supported by a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group to fund key clinical milestones through Phase 2b and into Phase 3 development.

United Therapeutics Acquires Thymmune Therapeutics

July 3, 2026

Biotechnology

United Therapeutics announced it has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing thymic regenerative cell therapies. The deal includes $140 million paid in cash upfront, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger

February 24, 2023

Pharmaceuticals

MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. entered into a definitive merger agreement for an all-stock transaction to form a combined clinical-stage oncology company. The merged organization will advance a pipeline of three clinical-stage oncology drug candidates, including eganelisib, voruciclib, and ME-344.

Norstella and Citeline Merge to Create $5B Global Pharma Technology Company

June 28, 2022

Data & Analytics

Norstella (the group of Evaluate, MMIT, Panalgo and The Dedham Group) announced an agreement to merge with Citeline (formerly Pharma Intelligence) to form a combined global pharmaceutical technology and intelligence business valued at about $5 billion. The combination brings clinical trial intelligence, commercial data and real‑world analytics together to offer an end‑to‑end suite of solutions for life sciences companies; the deal involves financial sponsors including Hg (Norstella) and Warburg Pincus (Citeline).

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.